{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:47:15Z","timestamp":1792432035590,"version":"4.5.0"},"reference-count":7,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jcf.2024.03.010","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T16:53:47Z","timestamp":1710608027000},"page":"1007-1009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9905-7805","authenticated-orcid":false,"given":"Steffie E.M.","family":"Vonk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josje","family":"Altenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A.A.","family":"Math\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2275-1713","authenticated-orcid":false,"given":"E. Marleen","family":"Kemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.03.010_bib0001","series-title":"Summary of product characteristics - KAFTRIO","year":"2020"},{"issue":"8","key":"10.1016\/j.jcf.2024.03.010_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14081674","article-title":"Therapeutic drug monitoring of ivacaftor, lumacaftor, tezacaftor, and elexacaftor in cystic fibrosis: where are we now?","volume":"14","author":"Choong","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.jcf.2024.03.010_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11060458","article-title":"CFTR modulators: does one dose fit all?","volume":"11","author":"van der Meer","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.jcf.2024.03.010_bib0004","article-title":"Stepwise introduction of elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and liver cirrhosis child-Pugh A or B using clinical and therapeutic drug monitoring: a case series","author":"Vonk","year":"2023","journal-title":"Clin Ther"},{"key":"10.1016\/j.jcf.2024.03.010_bib0005","article-title":"A quantitative method for the analysis of ivacaftor, hydroxymethyl ivacaftor, ivacaftor carboxylate, lumacaftor, and tezacaftor in plasma and sputum using LC-MS\/MS and its clinical applicability","author":"Vonk","year":"2020","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jcf.2024.03.010_bib0006","series-title":"Multi-discipline review trikafta (Elexacaftor\/Tezacaftor\/Ivacaftor)","article-title":"Chapter 6.3 - Comprehensive Clinical Pharmacology Review - Table 13","year":"2019"},{"issue":"12","key":"10.1016\/j.jcf.2024.03.010_bib0007","first-page":"614","article-title":"Biostatistics 104: correlational analysis","volume":"44","author":"Chan","year":"2003","journal-title":"Singapore Med J"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:15:37Z","timestamp":1788246937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1569199324000389"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.03.010","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}